Antibiotic Resistance Market Analysis - Global Industry Size, Share, Trends and Forecast 2022 - 2030
Select Access Type
DESCRIPTION
Antibiotic are medicines that are used to prevent various bacterial infections and antibiotic resistance is the inability of a microorganism to withstand the effects of an antibiotic. It is a specific type of drug resistance. These bacteria may infect humans and animals body, and the infections they cause are harder to treat than those caused by non-resistant bacteria. Hence, antibiotic resistance leads to higher medical costs and increased mortality. Nowadays, people are changing the way of antibiotic use and prescription. The report provides analysis of global antibiotic resistance market for the period 2015-2026, wherein 2018 to 2026 is the forecast period and 2017 is considered as the base year. The global antibiotic resistance market is anticipated to grow at considerable CAGR over 5.5% over the forecast period and reach US$ 12.11 Bn by 2026.
Report coverage
| Market | Antibiotic Resistance Market |
| Analysis Period | 2018 - 2026 |
| Base Year | 2018 |
| Forecast Data | 2018 - 2026 |
| Segments Covered | By Intervention, By Distribution Method and By Geography |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | TPfizer, Merck, Allergan, The Medicines Company, Melinta Therapeutics, Phage Technologies S.A, Tetraphase Pharmaceuticals, Nabriva Therapeutics. Macrolide Pharmaceuticals, Nemesis Bioscience, Westway Health, AmpliPhi Biosciences and BioVersys GmbH. |
| Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
| Customization Scope | 10 hrs of free customization and expert consultation |
Market Dynamics
Emergence of multi-drug resistant pathogens and growing need to prevent antibiotic effects are some of the fundamental factors which are responsible for the growth of the antibiotic resistance market globally. Growing clinical developments of antibiotic resistance is also fueling the growth of the market. International pharmaceutical organizations are mainly focusing on developing various advanced therapies for antibiotic resistance. Additionally, rise in incidence of chronic and infectious diseases across the globe and growing approach towards multiple clinical trials in order to treat various bacterial infections have led to the rapid growth of the global antibiotic resistance market. Favorable government legislation are creating various opportunities for market players. However, high cost and prolonged hospital stays are some of the factors that may hinder the growth of global antibiotic resistant market.
Market Segmentation
Market By Disease
- Complicated Urinary Tract Infection (cUTI)
- Complicated Intra-Abdominal Infections (cIAI)
- Blood Stream Infections (BSI)
- Clostridium difficile infections (CDI)
- Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
- Community Acquired Bacterial Pneumonia (CABP)
Market By Pathogen
- Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)
- Pseudomonas aeruginosa (Carbapenem-Resistant)
- Staphylococcus Aureus (Methicillin-Resistant)
- E. coli/K. pneumoniae (Carbapenem-Resistant)
- Streptococcus pneumoniae (Penicillin-Non-Susceptible)
- Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
- Enterococcus faecium (Vancomycin-Resistant)
- Haemophilus Influenzae (Ampicillin-Resistant)
Market By Drug Class
- Oxazolidinones
- Lipoglycopeptides
- Tetracyclines
- Cephalosporins
- Combination therapies
- Others
Market By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- Rest of MEA
The market research study on “Antibiotic Resistance Market (By Disease - cUTI, cIAI, BSI, CDI, ABSSSI, HABP/VABP, CABP; By Pathogen - Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, E. coli/K. Pneumoniae, Streptococcus Pneumoniae, Clostridium difficile, Enterococcus faecium, Haemophilus Influenzae; By Drug Class - Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination therapies, Others) - Global Industry Size, Share, Trends and Forecast 2018 - 2026” offers a detailed insights on Global antibiotic resistance market entailing insights on its different market segments. Market dynamics with drivers, restraints and opportunities with their impact are provided in the report. The report provides insights on global antibiotic resistance market by disease type, pathogen, drug class and major geographic regions. The report also covers basic healthcare development policies. Secondly, the report covers global antibiotic resistance market size and segment markets by disease type, pathogen, drug class and geography along with the information on companies operating in the market.
Market Participants
The global antibiotic resistance market is characterized by the presence of experienced and established players. Some of the key players include TPfizer, Merck, Allergan, The Medicines Company, Melinta Therapeutics, Phage Technologies S.A, Tetraphase Pharmaceuticals, Nabriva Therapeutics. Macrolide Pharmaceuticals, Nemesis Bioscience, Westway Health, AmpliPhi Biosciences and BioVersys GmbH. Industry participant battle on the basis of price, new innovated product launch, and expanding market presence.